ProPhase LabsPRPH +5.00% PB Ratio is 0.27 as of Jun. 29, 2026, which is 85% below its 10-year median of 1.76. The stock has 4 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, ProPhase Labs ranks better than 97.96% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), ProPhase Labs's share price is $0.105. ProPhase Labs's Book Value per Share for the quarter that ended in Dec. 2025 was $0.39. Hence, ProPhase Labs's PB Ratio of today is 0.27.
The historical rank and industry rank for ProPhase Labs's PB Ratio or its related term are showing as below:
PRPH'
s PB Ratio Range Over the Past 10 Years
Min: 0.19 Med: 1.76 Max: 17.58
Current: 0.27
During the past 13 years, ProPhase Labs's highest PB Ratio was 17.58. The lowest was 0.19. And the median was 1.76.
PRPH's PB Ratio is ranked better than 97.96% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.04
vs PRPH: 0.27
During the past 12 months, ProPhase Labs's average Book Value Per Share Growth Rate was -84.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -78.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -50.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -9.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ProPhase Labs was 115.90% per year. The lowest was -78.50% per year. And the median was -5.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ProPhase Labs PB Ratio Related Terms
ProPhase Labs PB Ratio Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, ProPhase Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ProPhase Labs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ProPhase Labs (PRPH) has a PB Ratio of 0.27 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ProPhase Labs and its competitors. This is 85% below median its historical median of 1.76. Over the past decade, ProPhase Labs' PB Ratio has ranged from 0.19 to 17.58. According to the industry distribution chart, ProPhase Labs ranks #4 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 2%.
Is ProPhase Labs' PB Ratio too high?
ProPhase Labs' current PB Ratio of 0.27 is 85% below median its 10-year median of 1.76. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 17.58. The Medical Diagnostics & Research industry median PB Ratio is 2.04. ProPhase Labs' value of 0.27 is 86.8% below this industry median. Based on the distribution chart, ProPhase Labs ranks #4 out of 196 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does ProPhase Labs' PB Ratio compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #4 out of 196 companies for PB Ratio. This places ProPhase Labs in the top 2% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.04. ProPhase Labs' value of 0.27 is 86.8% below this benchmark. Historically, ProPhase Labs' own PB Ratio has ranged from 0.19 to 17.58 over the past decade. While the company's 10-year median is 1.76 vs. the industry median of 2.04, ProPhase Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.04, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current PB Ratio of 0.27 is 86.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current PB Ratio is 0.27, which is 85% below median its own 10-year median of 1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.11 — trading 83.8% below its estimated fair value. The current PB Ratio is 0.27, which is 85% below median its 10-year median of 1.76 and 86.8% below the Medical Diagnostics & Research industry median of 2.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current PB Ratio is 0.27 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 